First Brands Group debt targeted by Apollo Global Management - report
NEW YORK/WALTHAM, MASS. - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company with a market capitalization of $853 million that has seen its shares surge over 12% in the past week, will host a conference call and webcast on Monday at 8:00 a.m. EDT to discuss results from its Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG), according to a company press release.
The clinical-stage biotechnology company, which focuses on developing antibody complement therapeutics for severe autoimmune diseases, will present findings from the study investigating claseprubart as a potential treatment for gMG, a chronic autoimmune neuromuscular disorder characterized by muscle weakness. According to InvestingPro data, analysts maintain a strong buy consensus on DNTH, with price targets ranging from $40 to $92.
Investors and interested parties can access the live webcast through the Investors and Media section of the company’s website. Those wishing to participate in the question and answer session must pre-register to receive dial-in information.
Dianthus Therapeutics, based in New York City and Waltham, Massachusetts, is developing monoclonal antibodies designed to treat severe autoimmune and inflammatory diseases. The company aims to create treatments with improved selectivity and potency compared to existing therapies.
A replay of the conference call will be available on the company’s website following the live event. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a current ratio of 13.12, indicating robust liquidity. Unlock 10+ additional InvestingPro Tips and comprehensive financial metrics to make informed investment decisions.
In other recent news, Dianthus Therapeutics is capturing attention as it approaches a crucial Phase II clinical trial data release for its generalized myasthenia gravis treatment, claseprubart (DNTH103). Guggenheim has reiterated its Buy rating for Dianthus Therapeutics, raising the stock’s price target to $92.00, emphasizing the potential impact of the upcoming trial results. The firm highlighted the trial as a significant catalyst, suggesting an asymmetric risk/reward opportunity for investors. Similarly, Cantor Fitzgerald has maintained its Overweight rating on Dianthus, naming it a "Top Pick" in anticipation of the September 2025 trial data. These developments underscore the high expectations surrounding the trial outcomes and their potential implications for the company.
In other company news, The Oncology Institute has appointed Anne McGeorge as the new Chairman of the Board, effective August 12, 2025. McGeorge, who joined the board in 2021, brings extensive healthcare financial experience, having previously led Grant Thornton LLP’s Global Health Care and Life Sciences Practice. This leadership change follows the retirement of Richard Barasch and marks a significant transition for The Oncology Institute.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.